Trial ID or NCT#

NCT03856099

Status

not recruiting iconNOT RECRUITING

Purpose

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

Official Title

A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Seema Nagpal, MD
Seema Nagpal, MD
Neuro-oncologist
Clinical Associate Professor, Neurology & Neurological Sciences Clinical Associate Professor (By courtesy), Neurosurgery
Chirag Patel, MD, PhD
Chirag Patel, MD, PhD
Neuro-oncologist
Clinical Assistant Professor, Neurology & Neurological Sciences Clinical Assistant Professor, Radiology - Rad/Molecular Imaging Program at Stanford

Contact us to find out if this trial is right for you.

CONTACT

Hary Priya Yerraballa
(650) 724-9363